Senate Committee Turns 340B Spotlight on Drugmakers
Lawmakers turned their sharp scrutiny of the 340B program on drugmakers Tuesday, questioning why states and providers don’t know the ceiling prices within the drug discount program. In a hearing Tuesday, members of the Senate health committee asked government watchdogs why the Trump administration has delayed for the fifth time a rule that would set…